Beijing Tong Ren Tang Chinese Medicine Co., Ltd.

As of June 30, 2018, Beijing Tong Ren Tang Chinese Medicine Co., Ltd. carries a market capitalization of 13.46B, placing it among publicly traded companies globally. Its enterprise value stands at 11.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Beijing Tong Ren Tang Chinese Medicine Co., Ltd.'s next confirmed earnings release is scheduled for April 1, 2027.

As of June 30, 2018, Beijing Tong Ren Tang Chinese Medicine Co., Ltd. has 837.10M shares outstanding.

As of June 30, 2018, Beijing Tong Ren Tang Chinese Medicine Co., Ltd. trades at a trailing price-to-earnings ratio of 24.92. The price-to-sales ratio is 9.60, and the price-to-book ratio stands at 5.11.

As of June 30, 2018, Beijing Tong Ren Tang Chinese Medicine Co., Ltd. trades at an EV/EBITDA multiple of 17.57 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 8.28 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 17.57 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 11.60B versus a market cap of 13.46B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2018, Beijing Tong Ren Tang Chinese Medicine Co., Ltd. maintains a current ratio of 12.01, meaning it holds 12.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.04, indicating conservative leverage, while an interest coverage ratio of 24,450.44 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2018, Beijing Tong Ren Tang Chinese Medicine Co., Ltd. posted a return on equity (ROE) of 22.09, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 20.79 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 19.51, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 20.39, useful for judging operating efficiency across full business cycles. The company generates approximately 1.79M in revenue per employee across its workforce of 783.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.50 indicates how many times Beijing Tong Ren Tang Chinese Medicine Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2018, Beijing Tong Ren Tang Chinese Medicine Co., Ltd. recorded 115.71M in income tax expense. That works out to an effective tax rate of 17.16, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 674.21M, leaving 540.12M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Beijing Tong Ren Tang Chinese Medicine Co., Ltd.'s stock has declined approximately 36.10% over the past 52 weeks. The 50-day moving average sits at 5.91, while the 200-day moving average is 7.22.

Over the twelve months ended June 30, 2018, Beijing Tong Ren Tang Chinese Medicine Co., Ltd. generated 1.40B in revenue and converted that into 540.12M in net income, yielding earnings per share of 0.67. EBITDA reached 660.16M, while operating income came in at 657.67M.

As of June 30, 2018, Beijing Tong Ren Tang Chinese Medicine Co., Ltd. holds 1.97B in cash and equivalents against 1.14M in total debt, resulting in a net debt position of -412.00M. Total book value stands at 2.64B, with working capital of 2.32B providing operational flexibility.

Over the twelve months ended June 30, 2018, Beijing Tong Ren Tang Chinese Medicine Co., Ltd. posted a gross margin of 71.66, reflecting its pricing power and cost economics. The operating margin of 46.92 and net profit margin of 38.53 provide insight into operational efficiency.

As of June 30, 2018, Beijing Tong Ren Tang Chinese Medicine Co., Ltd. has an Altman Z-Score of 40.38, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.